Introduction
Atopic Dermatitis (AD) or Atopic Eczema (AE) is a chronic relapsing, inflammatory skin disease 1 . It is characterized by typically distributed multiple skin lesions with erythema, episodes of intense pruritus, papules, excoriations, erosions accompanied by a serous exudate, lichenification and dry skin. Atopic patients are susceptible to develop cutaneous infections and a wide variety of cutaneous changes 1 . It frequently affects children. Symptoms develop in 65% of children before 1 year of age and in 90% by 5 years of age. Sixty percent of the atopic children remain symptomatic in adulthood with recurrent flares that may be severe and sometimes debilitating 2 . The prevalence of atopic dermatitis in industrialized countries is 15 to 30% in children and 2 to 10% in adults 3 . Several symptoms including sleep disturbances, changes in activity, irritability, and self-consciousness have been reported in children with AD 2 . The mainstay of therapy for AD, including mild to moderate disease, has been the liberal use of emollients and topical corticosteroids 4 . Avoidance of allergens and other triggering factors are necessary for prevention of flares.
Severe cases may require systemic corticosteroids, phototherapy with ultraviolet light types A and B (UVA and UVB), and/or immunosuppressant drugs. However, the adverse effects of stronger topical corticosteroids such as striae, atrophy, and telangiectasia limit the long-term use of these agents. When topical corticosteroids are applied to extensive body surface areas (BSAs), they can be absorbed systemically, and causes complications like Cushing's syndrome, adrenal suppression, and loss of bone density, hypertension, cataracts, and growth retardation in children 5 . The degree of systemic absorption of corticosteroids varies depending on the potency and amount of the drug applied, the nature and extent of affected skin etc. The drug penetration is more rapid and extensive in areas like face, eyelids, and genitals. For this reason, mid to high potency corticosteroids are not used routinely on these areas. Topical immune-modulators, antihistamines, and antibiotics are now being used for the treatment of AD. Tacrolimus ointment (0.03% and 0.1%) has clinically shown to reduce the extent, severity and symptoms of moderate to severe AD in children. It has been considered to be safe and effective for long-term use for up to 4 years 6 . Data collection: Clinical, laboratory and follow up findings for each individual patient were collected in a predesigned data collection sheet.
Materials & Methods

Data analysis:
Collected data were compiled and entered into computer based software, Statistical Package for Social Sciences (SPSS) for windows version 16. The continuous data were expressed as mean ± SD. The difference in mean between two groups was calculated by students't' test. The categorical data were expressed as frequency, proportion and percentage and the difference between groups was calculated by chi-square test. P value <0.05 was considered as minimum level of significance.
The result was expressed as frequency, percentage, mean±SD and shown in tables and graphs. Analysis revealed that there was no significant difference between two groups in terms of presence of family history of atopic dermatitis (p=0.313), personal history of atopic dermatitis (p=0.153) and duration of sufferings (p=0.837). in hydrocortisone group respectively. The tacrolimus group had highly significant improvement than hydrocortisone group at all these follow up (p< .001) (Fig-1) . The mean ±SD overall percentage improvement from base was 89.73±4.77% in tacrolimus group and 66.20±6.05% in hydrocortisone group. The improvement was significantly high in tacrolimus group (p<0.001) than hydrocortisone group) ( Table-II) . Improvement, p value derived from Chi-square test Excellent, marked and moderate improvement were observed in 19(63.3%), 9(30.0%), and 2(6.7%) patients respectively in tacrolimus group. In hydrocortisone group excellent, marked and moderate improvement were observed in 1(3.3%), 2(6.7%) and 27(90.0%) patients respectively. Tacrolimus group had better improvement than hydrocortisone group (p<0.001). Table- III: Distribution of patients by adverse effect like skin burning at application site (n=60).
Group A = Tacrolimus group, Group B = Hydrocortisone group, p value derived from chi-square test.
Adverse effects like skin burning at application site at 1 week were observed in 8(26.7%) patients of tacrolimus group and in 2(6.7%) patients of hydrocortisone group. Tacrolimus group had significantly more skin burning at 1 week at application site (p=0.038). Although, skin burning at application site at 12 weeks was observed in 2(6.7%) patients of tacrolimus group and 1(3.3%) of hydrocortisone group, this difference was not statistically significant (p=0.554). Flu syndrome as non-application site adverse effect was observed in 1(3.3%) patient of tacrolimus group and none of hydrocortisone group. This difference in flu syndrome between two groups was not statistically significant (p=0.313) ( Table-III) .
Discussion
When tacrolimus ointment is used to treat moderate to severe Atopic Dermatitis (AD), children generally respond to treatment within the first week with an improvement in signs and symptoms. In the physician's global evaluation of clinical response, excellent, marked and moderate improvement was observed in 19(63.3%), 9(30.0%) and 2(6.7%) patients of tacrolimus group and 1(3.3%), 2(6.7%) and 27(90.0%) patients in hydrocortisone group respectively. Tacrolimus group had better improvement than hydrocortisone group (p<0.001). This result coincides with previous studies done by Alaiti et al (1998) 11 .
Overall percentage Improvement from base
Tacrolimus ointment, a topical immunomodulator, has been available since December 2000. It is indicated for short-term and intermittent long-term therapy of both adult and pediatric patients with moderate to severe AD. Tacrolimus acts through inhibition of calcineurin to suppress T-cell activation, inhibit inflammatory cytokine release, and reduce the stimulatory activity of antigen-presenting cells. Topical application of tacrolimus ointment results in minimal systemic absorption. It does not cause a decrease in collagen synthesis or skin thickness 12 .
Conclusion
Tacrolimus ointment is more effective than hydrocortisone acetate in the treatment of atopic dermatitis in paediatric patients. It is also safe for long term use. Because tacrolimus ointment does not cause skin atrophy, it may be safely used for longer periods on all skin areas, including the face and intertriginous area.
